Title: SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Status: Recruiting For more information about this trial, contact: AeRang Kim, M.D., Ph.D
Age plays a significant role, as collagen production naturally decreases after age 25, reducing the skins ability to bounce back
Abeta peptide and Alzheimers disease: celebrating a century of research
Is Chicnutrix Glow safe for daily consumption
You can, but it won't undo any heat damage that may have occurred
Fasting is a powerful physiological process that elicits various metabolic changes in the body, including the modulation of antioxidant levels